Dyne Therapeutics Stock Performance
| DYN Stock | USD 12.08 0.18 1.47% |
The firm shows a Beta (market volatility) of 1.81, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Dyne Therapeutics will likely underperform. At this point, Dyne Therapeutics has a negative expected return of -0.97%. Please make sure to confirm Dyne Therapeutics' potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if Dyne Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Dyne Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (1.47) | Five Day Return 0.42 | Year To Date Return (52.55) | Ten Year Return (49.46) | All Time Return (49.46) |
1 | Disposition of 2548 shares by High Susanna Gatti of Dyne Therapeutics at 31.89 subject to Rule 16b-3 | 01/14/2025 |
2 | Acquisition by Rhodes Jason P of 1111111 shares of Dyne Therapeutics at 13.5 subject to Rule 16b-3 | 01/27/2025 |
3 | FMR LLC Reduces Stake in Dyne Therapeutics Inc Analyzing the Implications | 02/12/2025 |
4 | Disposition of 2488 shares by Scalzo Richard William of Dyne Therapeutics at 13.95 subject to Rule 16b-3 | 02/18/2025 |
5 | Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 02/27/2025 |
6 | We Think Dyne Therapeutics Needs To Drive Business Growth Carefully | 02/28/2025 |
7 | Disposition of 1094 shares by Oxana Beskrovnaya of Dyne Therapeutics at 11.83 subject to Rule 16b-3 | 03/05/2025 |
8 | Dyne Therapeutics Now Covered by Analysts at Scotiabank | 03/07/2025 |
9 | Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum | 03/11/2025 |
10 | Dyne Therapeutics Sets New 12-Month Low Heres What Happened | 03/13/2025 |
11 | Disposition of 1343 shares by Kerr Douglas of Dyne Therapeutics at 11.83 subject to Rule 16b-3 | 03/14/2025 |
12 | Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer | 03/20/2025 |
| Begin Period Cash Flow | 123.9 M | |
| Free Cash Flow | -294.7 M |
Dyne |
Dyne Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,391 in Dyne Therapeutics on December 22, 2024 and sell it today you would lose (1,183) from holding Dyne Therapeutics or give up 49.48% of portfolio value over 90 days. Dyne Therapeutics is generating negative expected returns assuming volatility of 5.3744% on return distribution over 90 days investment horizon. In other words, 47% of stocks are less volatile than Dyne, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Dyne Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Dyne Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Dyne Therapeutics, and traders can use it to determine the average amount a Dyne Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1802
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DYN |
Estimated Market Risk
| 5.37 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.97 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dyne Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dyne Therapeutics by adding Dyne Therapeutics to a well-diversified portfolio.
Dyne Therapeutics Fundamentals Growth
Dyne Stock prices reflect investors' perceptions of the future prospects and financial health of Dyne Therapeutics, and Dyne Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dyne Stock performance.
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.5 | ||||
| Current Valuation | 784.42 M | ||||
| Shares Outstanding | 113.12 M | ||||
| Price To Earning | 35.58 X | ||||
| Price To Book | 2.23 X | ||||
| EBITDA | (343.89 M) | ||||
| Net Income | (317.42 M) | ||||
| Cash And Equivalents | 291.84 M | ||||
| Cash Per Share | 5.64 X | ||||
| Total Debt | 23.99 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.63 X | ||||
| Book Value Per Share | 6.16 X | ||||
| Cash Flow From Operations | (292.37 M) | ||||
| Earnings Per Share | (3.37) X | ||||
| Market Capitalization | 1.39 B | ||||
| Total Asset | 691.23 M | ||||
| Retained Earnings | (949.93 M) | ||||
| Working Capital | 617.02 M | ||||
| Current Asset | 1.93 B | ||||
| Current Liabilities | 809 M | ||||
About Dyne Therapeutics Performance
By examining Dyne Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Dyne Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Dyne Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.86 | 48.73 | |
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.53) | (0.56) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.50) | (0.53) |
Things to note about Dyne Therapeutics performance evaluation
Checking the ongoing alerts about Dyne Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dyne Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dyne Therapeutics generated a negative expected return over the last 90 days | |
| Dyne Therapeutics has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (317.42 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne Therapeutics has about 291.84 M in cash with (292.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer |
- Analyzing Dyne Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dyne Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dyne Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dyne Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dyne Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dyne Therapeutics' stock. These opinions can provide insight into Dyne Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.